



Gennex Laboratories Limited

"AKASH GANGA" 3rd Floor, Plot No.144, Srinagar Colony, Hyderabad - 500073. Telangana, INDIA
Tel : +91-40-67334400 (30Lines), 23746451, Fax : +91-40-67334433
Email: info@gennexlab.com | www.gennexlab.com
CIN : L24230TG1990PLCO11168

Ref: GLL/Board/2019-20/0012

Date: 30/05/2019.

To
Dy. General Manager,
BSE Ltd.,
Phiroje Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

To
Asst. Manager (Listing)
The Ahmedabad Stock Exchange Ltd.,
Kamdheni Complex, Opp.Sahajanand College,
Ahmedabad – 380 015.

To
The Secretary
The Calcutta Stock Exchange Association Ltd.,
7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

Subject : Outcome of Board Meeting held today & Submission of Audited Financial Result for the 4th Quarter and Year Ended 31st March, 2019.


Reference : Security ID : GENNEX & Script Code – 531739

Further to our letter dated.20.05.2019, in compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015, please find enclosed herewith the Audited Financial Results (Standalone and Consolidated) for the 4th Quarter and year ended 31st March, 2019 and Auditors' Report and Form B (for Audit Report on modified opinion) and declaration pursuant to Regulation 33 (3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, as approved by the Board of Directors at their meeting held today i.e, 30th May, 2019 at 04.30 P.M. and concluded at. 09:15 P.M.

Kindly bring this to the notice of the members of the Exchange.

Thanking You,

Yours faithfully,
For Gennex Laboratories Ltd.,


Authorized Signatory

Encl: as above



Gennex Laboratories Limited

"AKASH GANGA" 3rd Floor, Plot No.144, Srinagar Colony, Hyderabad - 500073, Telangana, INDIA
Tel : +91-40-67334400 (30Lines), 23746451, Fax : +91-40-67334433
Email: info@gennexlab.com | www.gennexlab.com
CIN : L24230TG1990PLCO11168

Ref: GLL/Board/2019-12/0012

Date: 30/05/2019.

To
Dy. General Manager,
BSE Ltd.,
Phiroje Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

To
Asst. Manager (Listing)
The Ahmedabad Stock Exchange Ltd.,
Kamdheni Complex, Opp.Sahajanand College,
Ahmedabad – 380 015.

To
The Secretary
The Calcutta Stock Exchange Association Ltd.,
7, Lyons Range, Calcutta – 700 001.

Dear Sir/Madam,

**Subject : Announcement of audited financial results for the Year Ended
March 31, 2019 together with the Auditors Report as Annexure – I.**
Reference : Reg. 30(2) and Reg.33 of SEBI (LODR) Regulations, 2015.


This is to inform you that the Audited Financial Results for the year ended March 31, 2019 was approved and taken on record by the Board of Directors at their meeting held on May 30, 2019. The same was signed by Mr. T.M. Gopalakrishnan, Executive Director of the Company and we enclose Audited Financial Results for the year ended March 31, 2019 together with Auditors Report as Annexure – I. We are arranging publication of the Results in the newspaper and also upload on the website of the Company as required under Reg.33 read with 47 of SEBI (LODR) Regulations, 2015.

The Meeting commenced at 04.30 P.M. and concluded at 09:15 P.M.

Kindly bring this to the notice of the Members of the Exchange.

Thanking You,

Yours faithfully,
For Gennex Laboratories Ltd.,


Authorised Signatory

Encl: as above

GENNEX LABORATORIES LIMITED
Registered Office : Sy.No.133, Bollaram, Jinnaram Mandal,
Dist : Sangareddy, Telangana - 502 325. INDIA
CIN : L24230TG1990PLC011168

Statement of Standalone and Consolidated Audited Financial Results for the Quarter and Year Ended 31st March, 2019

S No.	PARTICULARS	Quarter ended		Standalone - Year Ended		(Rs. In Lacs)		
		31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018	31.03.2019	31.03.2018
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Income							
	Revenue from Operations	2036.07	1521.55	1347.27	5580.27	4377.88	5580.27	4377.88
	Other Income	25.03	20.52	72.71	78.25	90.36	78.25	90.36
	Total Income	2061.10	1542.07	1419.98	5658.52	4468.24	5658.52	4468.24
2	Expenses							
(a)	Cost of material consumed	1213.16	939.82	774.41	3468.05	2567.72	3468.05	2567.72
(b)	Purchase of stock-in-trade	37.59	0.00	16.50	40.52	30.01	40.52	30.01
(c)	Changes in stock-in-trade and Work in Progress and stock in trade	-18.52	-34.60	131.65	-238.82	75.42	-238.82	75.42
(d)	Employees Cost	180.78	167.93	184.11	612.20	554.57	612.20	554.57
(e)	Depreciation	19.46	30.51	18.82	98.47	92.18	98.47	92.18
(f)	Finance Cost	20.29	25.65	23.67	79.38	73.11	79.38	73.11
(g)	Other Expenses	483.06	330.83	251.62	1296.00	930.89	1296.00	930.89
	Total Expenses	1935.81	1460.14	1400.78	5355.79	4323.90	5355.79	4323.90
3	Total Profit before exceptional Items & Tax.	125.28	81.93	19.20	302.72	144.34	302.72	144.34
4	Exceptional items	0.00	0.00	0.00	0.00	1.00	0.00	1.00
5	Total profit before tax	125.28	81.93	19.20	302.72	145.34	302.72	145.34
6	Tax expense for earlier years	-0.15	0.00	-40.72	-0.15	-61.13	-0.15	-61.13
7	Current tax	-85.00	0.00	-35.00	-85.00	-35.00	-85.00	-35.00
8	Deferred Tax	4.51	0.00	34.37	4.51	34.37	4.51	34.37
9	Total Tax Expenses	-80.65	0.00	-41.35	-80.64	-61.76	-80.64	-61.76
10	Net profit (Loss)	44.63	81.93	-22.15	222.08	83.58	222.08	83.58
11	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	(8.08)	(0.95)
12	Total Profit (loss) for period	44.63	81.93	-22.15	222.08	83.58	214.00	82.63
13	Other comprehensive income net of taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00
14	Total Comprehensive income for the period							
	Total profit or loss, attributable to	44.63	81.93	-22.15	222.08	83.58	214.00	82.63
	Profit or loss, attributable to owners of parent							
15	Total Comprehensive income for the period attributable to							
	Comprehensive income for the period attributable to owners of parent							
	Total comprehensive income for the period attributable to owners of parent non controlling interests							
16	Details of equity share capital							
	Paid up equity share capital	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03
	Face value of equity share capital	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001
17	Earnings per share							
	- Basic	0.035	0.065	-0.018	0.176	0.066	0.169	0.065
	- Diluted	0.035	0.065	-0.018	0.176	0.066	0.169	0.065

NOTES to the results:

- The above audited financial results have been reviewed by the Audit Committee of the Board of Directors and taken on record at the meeting of Board of Directors held on May 30, 2019.
- The statement has been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 (IndAS) prescribed under section 133 of Companies Act, 2013 and other prescribed accounting practices and policies to the extent possible.
- The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Operating Segment and believes that the Company has only one reportable segment namely " Bulk Drugs, Biotech Products and Intermediates".
- The Figures for the Quarter ended 31-March-2019 and the corresponding quarter ended in the Previous year, as reported in these financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subject to audit. Previously period/year figures have been regrouped/reclassified wherever necessary.

For Gennex Laboratories Limited
Sd/-

T.M.Gopalakrishnan
Whole Time Director

Place: Hyderabad
Date: 30.05.2019

GENNEX LABORATORIES LIMITED

Registered Office : Sy.No.133, Bollaram, Jinnaram Mandal,

Dist : Sangareddy, Telangana - 502 325. INDIA

CIN : L24230TG1990PLC011168

Statement of Assets and Liabilities as at March, 2019

Sl.no	Particulars	Standalone		Consolidated	
		As at 31-Mar-19 Audited in Lakhs	As at 31-Mar-18 Audited in Lakhs	As at 31-Mar-19 Audited in Lakhs	As at 31-Mar-18 Audited in Lakhs
1	Non-Current Assets				
	Property, Plant and Equipment	1,563.81	1,558.13	1,563.81	1,558.13
	Capital work-in-progress	-	-	-	-
	Investment property	-	-	-	-
	Goodwill	-	-	-	-
	Financial Assets				
	Investments in Associate	700.00	700.00	690.97	699.05
	Other Investments	1.00	1.00	1.00	1.00
	Loans, non-current	-	-	-	-
	Other non-current financial assets	-	-	-	-
	Deferred Tax Assets (Net)	-	-	-	-
	Other Non-current Assets	22.24	22.21	22.24	22.21
	Total non-current assets	2,287.04	2,281.34	2,278.01	2,280.39
2	CURRENT ASSETS				
	Inventories	532.71	233.86	532.71	233.86
	Financial Assets				
	Trade receivables, current	1,039.78	1,045.91	1,039.78	1,045.91
	Cash and Cash Equivalents	19.51	5.66	19.51	5.66
	Bank balance other than cash and cash equivalents	295.14	96.17	295.14	96.17
	Other current financial assets	1,014.32	1,381.94	1,014.32	1,381.94
	Total Current financial assets	2,368.75	2,529.68	2,368.75	2,529.68
	Current tax assets (net)	-	-	-	-
	Other Current Assets	2.80	3.50	2.80	3.50
	Total Current Assets	2,904.26	2,767.04	2,904.26	2,767.04
	Total Assets	5,191.30	5,048.38	5,182.28	5,047.43
	EQUITY AND LIABILITIES				
1	EQUITY				
	Equity attributable to owners of parent				
	Equity Share capital	1,265.03	1,265.03	1,265.03	1,265.03
	Other Equity	2,134.74	1,912.67	2,125.72	1,911.72
	Total Equity	3,399.77	3,177.70	3,390.75	3,176.75
2	LIABILITIES				
	Non-current Liabilities				
	Financial Liabilities:				
	Borrowings	0.00	34.86	0.00	34.86
	Other financial liabilities	-	-	-	-
	Total non current financial liabilities	0.00	34.86	0.00	34.86
	Other Non current Liabilities:				
	Deffered tax liabilities (Net)	56.01	60.51	56.01	60.51
	Deferred Government Grants, Non-current	5.49	8.27	5.49	8.27
	Total Non-Current liabilities	61.51	103.64	61.51	103.64
	Current Liabilities				
	Financial liabilities				
	Borrowings	453.87	212.16	453.87	212.16
	Trade payables	815.44	1,235.88	815.44	1,235.88
	Other financial liabilities	315.08	270.97	315.08	270.97
	Total Current financial liabilities	1,584.40	1,719.01	1,584.40	1,719.01
	Other current liabilities				
	Provisions, current	17.11	46.29	17.11	46.29
	Current Tax Liabilities (Net)	125.75	-	125.75	-
	Deferred Government Grants, Current	2.78	1.74	2.78	1.74
	Total current liabilities	145.64	48.03	145.64	48.03
	Total Liabilities	1,791.54	1,870.68	1,791.54	1,870.68
	Total Equity and liabilities	5,191.32	5,048.38	5,182.29	5,047.43
	Disclosure of notes on assets and liabilities				

**INDEPENDENT AUDITOR'S REPORT
TO THE BOARD OF DIRECTORS OF
GENNEX LABORATORIES LIMITED**

1. We have audited the accompanying statement of Standalone financial results of **Gennex Laboratories Limited** ("the company") for the Quarter and Year ended March 31, 2019 ("the Statement"), attached hereto being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations') as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, which has been initiated by us for the purpose of identification.
2. The Statement and the Standalone Annual Financial Statements which form the basis for this Statement are the responsibility of the Company's Management and have been reviewed by the Audit Committee and approved by its Board of Directors, and have been prepared in accordance with the Accounting Standard prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules there under, as applicable, and other accounting Principles generally accepted in India. Our responsibility is to express an opinion on the Standalone Financial Statements, based on our audit thereof.
3. We conducted our Audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves examining on test basis and performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statement. The procedures selected depend on the auditors' judgement, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditors consider internal financial control relevant to the entity's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal financial control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



4. **BASIS FOR QUALIFIED OPINION**

The Balances of Current Assets, Other Non-Current Assets, Non Current Liabilities, Other Non-Current Liabilities, Current Liabilities and other Current Liabilities are subject to confirmations/reconciliations. The Impact of the same is, unascertained.

5. **QUALIFIED OPINION**

In our opinion and to best of our information and according to the explanations given to us and based on the consideration of the reports of the other Auditors on separate Financial Statements of the Branch, except for the possible effects of the matters described in the Basis for Qualified Opinion paragraph;

- i. the Statement, together with the notes thereon are presented in the format prescribed under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 and SEBI Circular dated 5 July 2016; and
- ii. the statement, gives true and fair view in conformity with Ind AS and other Accounting Principles generally accepted in India of the profit for the quarter and profit for the year, the total Comprehensive Income and other financial information of the Company for the Quarter and year ended 31st March, 2018.

6. **EMPHASIS OF MATTER**

The Financial Statement which describes pending registration formalities for land acquired. Our opinion is not qualified in respect of this matter.

7. The above financial statements include Statement of Branch of the company which has been audited by other auditors whose report have been furnished to us by the management and our opinion on the branch financial results, in so far as it relates to the amounts and disclosures included in respect of the branch is based solely on the reports of the other auditors



For PPKG & Co.,
Chartered Accountants

Girdhari Lal Toshniwal
Girdhari Lal Toshniwal
Partner

M.No. 205140
Frn No. 009655S

Place: Hyderabad
Date: 30.05.2019

**INDEPENDENT AUDITOR'S REPORT
TO THE BOARD OF DIRECTORS OF
GENNEX LABORATORIES LIMITED**

1. We have audited the accompanying statement of Consolidated financial results of **Gennex Laboratories Limited** ("the company") and its Associate (together referred as "the Group") for the Quarter and Year ended March 31, 2019 ("the Statement"), attached hereto being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('Listing Regulations') as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, which has been initiated by us for the purpose of identification.
2. The Statement and the Consolidated Annual Financial Statements which form the basis for this Statement are the responsibility of the Company's Management and have been reviewed by the Audit Committee and approved by its Board of Directors, and have been prepared in accordance with the Accounting Standard prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules there under, as applicable, and other accounting Principles generally accepted in India. Our responsibility is to express an opinion on the Consolidated Financial Statements, based on our audit thereof.
3. We conducted our Audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves examining on test basis and performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statement. The procedures selected depend on the auditors' judgement, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditors consider internal financial control relevant to the entity's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal financial control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



4. **BASIS FOR QUALIFIED OPINION**

The Balances of Current Assets, Other Non-Current Assets, Non Current Liabilities, Other Non-Current Liabilities, Current Liabilities and other Current Liabilities are subject to confirmations/reconciliations. The Impact of the same is, unascertained.

5. **QUALIFIED OPINION**

In our opinion and to best of our information and according to the explanations given to us and based on the consideration of the reports of the other Auditors on separate Financial Statements of the Associate and Branch, except for the possible effects of the matters described in the Basis for Qualified Opinion paragraph;

- i. the Statement, together with the notes thereon are presented in the format prescribed under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 and SEBI Circular dated 5 July 2016; and
- ii. the statement, gives true and fair view in conformity with Ind AS and other Accounting Principles generally accepted in India of the profit for the quarter and profit for the year, the total Comprehensive Income and other financial information of the Company for the Quarter and year ended 31st March, 2019.

6. **EMPHASIS OF MATTER**

The Financial Statement which describes pending registration formalities for land acquired. Our opinion is not qualified in respect of this matter.

7. We did not audit the financials statements of Associate Company and Company's Branches which are included in the Consolidated Financial results. These financial statements have been audited by other auditors whose report have been furnished to us by the management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this Associate and Branch is based solely on the reports of the other auditors.



For PPKG & Co.,
Chartered Accountants









Girdhari Lal Toshniwal
Girdhari Lal Toshniwal
Partner

M.No. 205140
FRN.No. 009655S

Place: Hyderabad
Date: 30.05.2019

"FORM B"

**[Pursuant to Regulation 33(3)(d) of Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations**

1. Name of the Company	Gennex Laboratories Limited
2. Annual financial statement for the year ended	31st March 2019
3. Type of Audit qualification	Qualified
4. Frequency of qualification	The below mentioned qualification that appears in the Balance Sheet is repetitive
5. Draw attention to relevant notes in the annual financial statements and management response to the qualification in the directors report.	<p>Observation The Balances of Current Assets, other Non-Current Assets, Non-Current Liabilities, Other Non-Current Liabilities, Current Liabilities & other Current Liabilities are subject to confirmations/reconciliations. The Impact of the same is unascertained.</p> <p>Management Response As pointed out by the Statutory Auditors, the company has not obtained confirmation of balances of Advances, Deposits, Unsecured Loans, other liabilities, Trade Receivables, Trade Payables and advance against Suppliers. The Company has made best of its efforts to obtain the same before signing the accounts for current financial year as well as for last financial year. Further, the management of the company confirms that balances shown in the books are true and correct as per their knowledge</p>
6. Additional comments for the board/audit committee chair	The Audit Committee took note of same and Formulated appropriate policies to avoid the same in future.
<p>7. To be signed by-</p> <p>For Gennex Laboratories Limited</p>   <p>T M Gopala Krishnan Executive Director Din. No.: 03137458</p> <p>For Gennex Laboratories Limited</p>   <p>Y. Ravinder Reddy Chairman, Audit Committee Din. No.: 00011040</p>	<p>For Gennex Laboratories Limited</p>   <p>Laxmipat Baid Chief Finance Officer</p> <p>Auditor of the Company For PPKG & Co. (Firm No. 009655 S)</p>   <p>(Giridhari Lal Toshniwal) Partner M.No.205140</p>